Clavis Pharma appoints chief business officer
Nicholas Adams takes the role at Norwegian firm
For the past 12 years, Adams worked for the UK cancer company, Antisoma plc, the majority of the time as vice president business development and a member of the senior management team.
Prior to this, he spent 11 years in various positions at Ciba-Geigy (now Novartis), Eisai and Covance.
Olav Hellebø, ceo of Clavis Pharma, said Adams brings to the company considerable experience in business development, particularly in building partnerships with leading pharmaceutical companies, and with a strong focus in oncology.
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Research & Development
Nuclera and University of Cambridge researchers demonstrate rapid structural analysis of challenging drug target
Collaboration combines cell-free protein synthesis, proprietary nanodisc technology and cryo-electron microscopy (cryo-EM) for high-resolution structural analysis of a G protein-coupled receptor (GPCR)
Research & Development
Evotec secures $2.9m grant to advance stem cell-based drug safety testing
The three-year Gates Foundation grant will support Evotec's human induced pluripotent stem cell platform, helping global health researchers identify potential developmental toxicity risks earlier in drug discovery